Kypha, a St. Louis-based medical startup company has raised another $950,000, according to a filing with the Securities and Exchange Commission.
Kypha, located at 4320 Forest Park Ave, is developing specialized biomarker testing solutions for monitoring immune status and inflammation.
The new equity investments comes from one unnamed investor, according to the SEC filing.
Earlier this month, the medical device company acquired Ireland-based Biosensia, a diagnostics platform and contract development company. The terms of the deal were not disclosed.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
According to co-founder and CEO Chad Stiening, the SEC filing is in regards to its acquisition of Biosensia.
In May, Kypha raised $1.6 million from 13 investors as part of a larger $4 million offering, according to a regulatory filing.
Kypha moved to St. Louis from Kentucky in 2011 after investment from Missouri Technology Corp., and BioGenerator and incentives from the Missouri Department of Economic Development, the St. Louis Development Corp. and the St. Louis Regional Chamber.
Date: July 30, 2018
Source: bizjournals
